Qian Zhang1, Shimeng Liu2, Yumei Liu3, Yang Hua4, Haiqing Song1, Yi Ren1, Yang Song1, Ran Liu4, Wuwei Feng5, Bruce Ovbiagele5, Jianping Ding6, Xunming Ji7. 1. Department of Neurology, Xuanwu Hospital, Capital Medical University, 45 Changchun Street, Beijing 100053, China. 2. Department of Neurology, Xuanwu Hospital, Capital Medical University, 45 Changchun Street, Beijing 100053, China; Department of Neurology, Medical University of South Carolina, Charleston, SC 29464, USA. 3. Department of Neurology, Medical University of South Carolina, Charleston, SC 29464, USA; Vascular Ultrasound Department, Xuanwu Hospital, Capital Medical University, 45 Changchun Street, Beijing 100053, China. 4. Vascular Ultrasound Department, Xuanwu Hospital, Capital Medical University, 45 Changchun Street, Beijing 100053, China. 5. Department of Neurology, Medical University of South Carolina, Charleston, SC 29464, USA. 6. Department of Neurology, Xuanwu Hospital, Capital Medical University, 45 Changchun Street, Beijing 100053, China. Electronic address: djp192001@xwhosp.org. 7. Department of Neurology, Xuanwu Hospital, Capital Medical University, 45 Changchun Street, Beijing 100053, China. Electronic address: jixm@ccmu.edu.cn.
Abstract
OBJECTIVE: To assess whether an intensive lipid-lowering strategy is more beneficial on atherosclerotic plaque progression in the stroke survivors. METHODS: We retrospectively assessed data that was prospectively collected on 106 ischemic stroke patients from one academic stroke center. Patients with various degrees of common carotid artery atherosclerosis were followed for one year. Patients were classified into intensive lipid-lowering therapy (ILLT) group if they achieve low-density lipoprotein cholesterol (LDL-c)<70mg/dL (n=38) and conventional lipid-lowering therapy (CLLT) group if their LDL-c is within 70-120mg/dL (n=68) at end of one year. Carotid ultrasound was performed at baseline lipid-lowering therapy and at one year to characterize the plaques. RESULTS: Mean change in atherosclerotic plaque length was -1.4mm (95% CI: [-4.1, 1, 2]; P=0.27) in ILLT and 1.1mm in CLLP group (95% CI: [-0.9, 3.1]; P=0.27); no difference between groups (P=0.40). Atherosclerotic plaque thickness decreased by 0.2mm (95% CI: [-0.4, 0.03]; P=0.09) in ILLT group; while in CLLT group, thickness increased by 0.02mm after 1-year therapy (95%CI: [-0.1, 0.2]; P=0.77); no difference between groups (P=0.28). CONCLUSIONS: Achieving LDL-c<70mg/dL in ischemic stroke patients was associated with a trend of reducing atherosclerotic plaque progression at one year. Future larger studies are warranted.
OBJECTIVE: To assess whether an intensive lipid-lowering strategy is more beneficial on atherosclerotic plaque progression in the stroke survivors. METHODS: We retrospectively assessed data that was prospectively collected on 106 ischemic strokepatients from one academic stroke center. Patients with various degrees of common carotid artery atherosclerosis were followed for one year. Patients were classified into intensive lipid-lowering therapy (ILLT) group if they achieve low-density lipoprotein cholesterol (LDL-c)<70mg/dL (n=38) and conventional lipid-lowering therapy (CLLT) group if their LDL-c is within 70-120mg/dL (n=68) at end of one year. Carotid ultrasound was performed at baseline lipid-lowering therapy and at one year to characterize the plaques. RESULTS: Mean change in atherosclerotic plaque length was -1.4mm (95% CI: [-4.1, 1, 2]; P=0.27) in ILLT and 1.1mm in CLLP group (95% CI: [-0.9, 3.1]; P=0.27); no difference between groups (P=0.40). Atherosclerotic plaque thickness decreased by 0.2mm (95% CI: [-0.4, 0.03]; P=0.09) in ILLT group; while in CLLT group, thickness increased by 0.02mm after 1-year therapy (95%CI: [-0.1, 0.2]; P=0.77); no difference between groups (P=0.28). CONCLUSIONS: Achieving LDL-c<70mg/dL in ischemic strokepatients was associated with a trend of reducing atherosclerotic plaque progression at one year. Future larger studies are warranted.
Authors: Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin Journal: N Engl J Med Date: 2006-08-10 Impact factor: 91.245
Authors: Pierre Amarenco; Larry B Goldstein; Michael Szarek; Henrik Sillesen; Amy E Rudolph; Alfred Callahan; Michael Hennerici; Lisa Simunovic; Justin A Zivin; K Michael A Welch Journal: Stroke Date: 2007-10-25 Impact factor: 7.914
Authors: P-J Touboul; M G Hennerici; S Meairs; H Adams; P Amarenco; N Bornstein; L Csiba; M Desvarieux; S Ebrahim; R Hernandez Hernandez; M Jaff; S Kownator; T Naqvi; P Prati; T Rundek; M Sitzer; U Schminke; J-C Tardif; A Taylor; E Vicaut; K S Woo Journal: Cerebrovasc Dis Date: 2012-11-01 Impact factor: 2.762
Authors: C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins Journal: Lancet Date: 2010-11-08 Impact factor: 79.321